The utility of biomarkers in diagnosis of aspirin exacerbated respiratory disease

Respiratory Research

Table 1 Participant characteristics

	AERD [n = 240]	ATA [n = 226]	Control [n = 71]	p-value (ANOVA)	T-Test
Demographics
Age (yrs)	49.3 [0.8]	49.7 [1.0]	44.3 [1.6]	0.008
Gender [M/F]	74/166	68/158	35/36	0.007
BMI (kg/m²)	26.7 [0.3]	27.1 [0.4]	25.6 [1.0]
Duration of asthma (yrs)	18.8 [0.8]	15.2 [1.0]	n/a		< 0.0001
ACT; uncontrolled, n [%]	108 [46]	98 [46]	n/a
Medication use
High dose ICS/Oral CS, n (%)	63 (26)	37 (18)	n/a		0.03
High dose ICS > 500 (μg/d), n (%)	62 (26)	52 (25.5)	n/a
Low dose ICS ≤500 (μg/d), n (%)	78 (33)	92 (44.7)	n/a		0.008
No ICS or Oral CS, n (%)	3 (14)	25 (12.4)	n/a
Lung functions
FEV₁% predicted	79.8 [1.3]	86.6 [1.4]	n/a		0.0003
FEV₁ %FVC	68.8 [0.7]	74.8 [0.7]	n/a		< 0.0001

Mean (SEM); Definition of abbreviations: AERD Aspirin-Exacerbated Respiratory Disease, ATA Aspirin Tolerant Asthma, M Male, F Female, BMI Body mass index, FEV₁ Forced expiratory volume in 1 s, FVC Forced vital capacity, CS Corticosteroidsm, ICS Inhaled Corticosteroids

ISSN: 1465-993X